ACRS Aclaris Therapeutics Inc.

Aclaris Therapeutics to Participate in the 2024 Cantor Global Healthcare Conference

Aclaris Therapeutics to Participate in the 2024 Cantor Global Healthcare Conference

WAYNE, Pa., Sept. 10, 2024 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today announced that members of the Aclaris management team will participate in a fireside chat during the 2024 Cantor Global Healthcare Conference on Tuesday, September 17, 2024 at 8:00 AM ET in New York, New York.

A webcast of the fireside chat may be accessed through the “Events” page of the “Investors” section of Aclaris’ website, The webcast will be archived for at least 30 days on the Aclaris website.

About Aclaris Therapeutics, Inc.

Aclaris Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates to address the needs of patients with immuno-inflammatory diseases who lack satisfactory treatment options. The company has a multi-stage portfolio of drug candidates powered by a robust R&D engine exploring protein kinase regulation. For additional information, please visit

Aclaris Therapeutics Contact:



EN
10/09/2024

Underlying

ACRSAclaris Therapeutics Inc.

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Aclaris Therapeutics Inc.

Jonathan Moreland
  • Jonathan Moreland
Free Trial
TTSH Tile Shop Holdi...
RMAX RE/MAX Holdings... ... (+53)

InsiderInsights Weekly Report: November 23, 2024

InsiderInsights Ratings of Companies with Open-Market Form 4 Purchases; Sales Filed at the SEC on the date above. We separate the real investment intelligence from the noise. Saving you time, and improving your research process

TTSH TILE SHOP HOLDINGS INC.
RMAX RE/MAX HOLDINGS INC.
PSEC PROSPECT CAPITAL CORPORATION
PPSI PIONEER POWER SOLUTIONS
PBF PBF ENERGY INC. CLASS A
OPK OPKO HEALTH INC.
NMFC NEW MOUNTAIN FINANCE CORPORATION
MPAA MOTORCAR PARTS OF AMERICA INC.
GLP GLOBAL PARTNERS LP
EL ESTEE LAUDER COMPANIES INC. CLASS A
APPS DIGITAL TURBINE
ACRS ACLARIS THERAPEUTICS INC.
MEDP MEDPACE HOLDINGS INC.
ENPH ENPHASE ENERGY INC.
HTLD HEARTLAND EXPRESS INC.
RAIL FREIGHTCAR AMERICA INC.
SVRA SAVARA
MAV PIONEER MUNICIPAL HIGH INCOME ADVANTAGE TRUST
ANGI ANGI INC. CLASS A
SNBR SLEEP NUMBER CORPORATION
MHI PIONEER MUNICIPAL HIGH INCOME TRUST
MBIN MERCHANTS BANCORP
GRX THE GABELLI HEALTHCARE & WELLNESSRX TRUST
NOVA SUNNOVA ENERGY INTERNATIONAL
GRWG GROWGENERATION
PCB PACIFIC CITY FINANCIAL CORP
ENX EATON VANCE NEW YORK MUNICIPAL BOND FUND
ONEW ONEWATER MARINE
BDSX BIODESIX
CSU CAPITAL SENIOR LIVING
MODV MODIVCARE INC
GRNT GRANIT SKOPKE
UAN CVR PARTNERS LP
INBX INHIBRX
OSCR INC.
WOLF OSCAR HEALTH
CLVT WOLFSPEED INC
ZETA CLARIVATE PLC
RWAY ZETA GLOBAL HLDGS CORP
CGBD RUNWAY GROWTH FINANCE CORP
NXGL TCG BDC
BIGZ INC.
DOUG NEXGEL INC
KLG_w BLACKROCK INNOVATION AND GROWTH TST
EP DOUGLAS ELLIMAN INC
MIO WK KELLOGG CO
MDRR EMPIRE PETROLEUM CORP
BNTC PIONEER MUN HIGH INCOME OPPORTUNITIES FD INC
EVM MEDALIST DIVERSIFIED REIT INC.
FGF BENITEC BIOPHARMA INC
EATON VANCE INSD CALIF MUN BD FD
FG FINANCIAL GROUP
INC.
11/24/24 November 24, 2024 1 EN
Jonathan Moreland
  • Jonathan Moreland
Free Trial
TTSH Tile Shop Holdi...
RMAX RE/MAX Holdings... ... (+21)

InsiderInsights.com Daily Ratings Report: November 20, 2024

InsiderInsights Ratings of Companies with Open-Market Form 4 Purchases; Sales Filed at the SEC on the date above. We separate the real investment intelligence from the noise. Saving you time, and improving your research process

TTSH TILE SHOP HOLDINGS INC.
RMAX RE/MAX HOLDINGS INC.
RGEN REPLIGEN CORPORATION
PSEC PROSPECT CAPITAL CORPORATION
OPK OPKO HEALTH INC.
NMFC NEW MOUNTAIN FINANCE CORPORATION
IRWD IRONWOOD PHARMACEUTICALS INC. CLASS A
GLP GLOBAL PARTNERS LP
EL ESTEE LAUDER COMPANIES INC. CLASS A
AXSM AXSOME THERAPEUTICS
APPS DIGITAL TURBINE
ACRS ACLARIS THERAPEUTICS INC.
ENPH ENPHASE ENERGY INC.
HTLD HEARTLAND EXPRESS INC.
MBIN MERCHANTS BANCORP
FSLY FASTLY
NOVA SUNNOVA ENERGY INTERNATIONAL
GRWG GROWGENERATION
RWAY RUNWAY GROWTH FINANCE CORP
HYLN HYLIION HOLDINGS CORP.
SYRS SYROS PHARMACEUTICALS INC.
11/21/24 November 21, 2024 1 EN
 PRESS RELEASE
Free
ACRS Aclaris Therape...

Aclaris Therapeutics Announces $80 Million Private Placement

Aclaris Therapeutics Announces $80 Million Private Placement WAYNE, Pa., Nov. 18, 2024 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS) (the “Company” or “Aclaris”), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today announced that it has entered into a securities purchase agreement with a group of accredited investors for the private placement of 35,555,555 shares of common stock at a purchase price of $2.25 per share, for gross proceeds of approximately $80.0 million. The private placement is expect...

November 18, 2024 1 EN
 PRESS RELEASE
Free
ACRS Aclaris Therape...

Aclaris Therapeutics Announces Exclusive, Global License Agreement wit...

Aclaris Therapeutics Announces Exclusive, Global License Agreement with Biosion, Inc., adding Potential Best-in-Class Biologics Assets to Pipeline - Enhances Aclaris’ pipeline with complementary biologics portfolio -- Expands leadership team with addition of seasoned biotech executives -- Management to host conference call today at 8:30 AM ET - WAYNE, Pa., Nov. 18, 2024 (GLOBE NEWSWIRE) --  Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today announced that it has entered ...

November 18, 2024 1 EN
 PRESS RELEASE
Free
ACRS Aclaris Therape...

Aclaris Therapeutics Reports Third Quarter 2024 Financial Results and ...

Aclaris Therapeutics Reports Third Quarter 2024 Financial Results and Provides a Corporate Update – First Patient Dosed in ATI-2138 Phase 2a Trial in Atopic Dermatitis As Previously Announced;Top-line Data Anticipated in First Half of 2025 – WAYNE, Pa., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today announced its financial results for the third quarter of 2024 and provided a corporate update. "The third quarter of 2024 marked an imp...

November 6, 2024 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch